| Name | Title | Contact Details |
|---|
Cohen & Co is a professional services firm based in Cleveland, Ohio, founded in 1977. With over 800 employees across 15 offices in eight U.S. states, the firm specializes in tax, assurance, and advisory services. Its diverse client base includes privately held companies, public and private investment funds, fund advisers, and Fortune 1000 multinational enterprises. Recognized as one of the top 100 accounting firms in the United States by annual revenues, Cohen & Co fosters a disciplined culture focused on delivering results and personal commitment to clients. The firm emphasizes employee development and community involvement, partnering with institutions like Youngstown State University. Its service offerings include comprehensive tax planning, audit and assurance engagements, and consulting on business strategy and operational improvements, tailored to various industries such as investment management and multinational corporations.
DistroKid is a digital music distribution service based in the United States, founded in 2013 by Philip Kaplan. It emerged from a social media platform for musicians called Fandalism. DistroKid specializes in helping independent artists and labels distribute their music to major online retailers, including Spotify, Apple Music, Amazon Music, and YouTube Music. The company offers a range of services to support musicians, including music distribution, monetization of sales and streams, and metadata customization. DistroKid also provides storage solutions for music files and additional features like customized YouTube URLs and Digital Object Identifiers (DOIs). With a competitive pricing model, artists can upload unlimited songs and albums for an annual fee, while retaining 100% of their earnings. DistroKid has been utilized by various notable artists, showcasing its effectiveness in the DIY music distribution space.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
At Divcon Controls, our mission is to provide our customers with cost effective solutions to meet their exact building automation needs. We strive to accomplish this through technology, innovation, and award winning personal service. Simply put, with Divcon Controls and Delta Controls, integration is simplified, customers are satisfied.